<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02072070</url>
  </required_header>
  <id_info>
    <org_study_id>KS-TGC-01-3</org_study_id>
    <nct_id>NCT02072070</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety Study of TissueGene-C to Degenerative Arthritis</brief_title>
  <official_title>A Placebo Controlled, Double-blind, Randomized, Parallel-group, Multi-center Phase III Study to Determine the Efficacy and Safety of TissueGene-C in Patients With Degenerative Arthritis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Kolon Life Science</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Kolon Life Science</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether TissueGene-C, an allogeneic human&#xD;
      chondrocytes expressing Transforming Growth Factor(TGF)-b1, is effective and safe in patients&#xD;
      with degenerative arthritis.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      TissueGene-C is a biological new drug which consists of normal chondrocyte cells and&#xD;
      transduced chondrocyte cells that express growth factor to modify osteoarthritis symptom for&#xD;
      long term period.&#xD;
&#xD;
      During the Phase 3 clinical trial , we will compare TissueGene-C to placebo in 26, 52 weeks&#xD;
      trial with 156 outpatients who have osteoarthritis. The outpatients are randomized to&#xD;
      TissueGene-C or placebo in 1:1 ratio, and they will be monitored and recorded in terms of&#xD;
      alleviating symptoms, sports activities, function of the knee, and the presence of adverse&#xD;
      events.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 2013</start_date>
  <completion_date type="Actual">August 2015</completion_date>
  <primary_completion_date type="Actual">August 2015</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Changes in IKDC scores</measure>
    <time_frame>Week 0 and 52</time_frame>
    <description>Symptoms, sports activities, and function of the knee will be measured by the International Knee Documentation Committee (IKDC)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Changes in 100 mm VAS scores</measure>
    <time_frame>Week 0 and 52</time_frame>
    <description>Pain of the knee will be measured by the 100mm Visual Analogue Scale (VAS)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Changes in WOMAC scores</measure>
    <time_frame>Wekk 0, 26, 39 and 52</time_frame>
    <description>Pain, stiffness, and physical function of the knee will be measured by the Western Ontario and McMaster Universities (WOMAC)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in KOOS scores</measure>
    <time_frame>Week 0, 26, 39 and 52</time_frame>
    <description>Symptoms, pain and functionality of the knee joint will be evaluated via the Knee Injury and Osteoarthritis Outcome Score (KOOS)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in MRI scan</measure>
    <time_frame>Week 0, 26 and 52</time_frame>
    <description>Comparison of pre-procedure MRI scans to those obtained at pre-dosing and at months 6 and 12 following dosing by an independent radiographic reviewer.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in Joint Space Width by an independent radiographic reviewer.</measure>
    <time_frame>Week 0, 26 and 52</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Level of Biomarkers in blood and urine.</measure>
    <time_frame>Week 0, 26, 39 and 52</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of Patients Use of Rescue Medication.</measure>
    <time_frame>Week 4, 12, 26, 39 and 52</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in IKDC scores</measure>
    <time_frame>Week 0, 26 and 39</time_frame>
    <description>Symptoms, sports activities, and function of the knee will be measured by the International Knee Documentation Committee (IKDC)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in 100 mm VAS scores</measure>
    <time_frame>Week 0, 26 and 39</time_frame>
    <description>Pain of the knee will be measured by the 100mm Visual Analogue Scale (VAS)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">163</enrollment>
  <condition>Degenerative Arthritis</condition>
  <arm_group>
    <arm_group_label>TissueGene-C</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single intra-articular injection to the damaged knee joint at a dose of 1.8 x 10^7 cells</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Single intra-articular injection to the damaged knee joint</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>TissueGene-C</intervention_name>
    <description>TissueGene-C at 1.8 x 10^7 cells</description>
    <arm_group_label>TissueGene-C</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo control(Normal Saline)</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Male or female patients at least 19 years of age&#xD;
&#xD;
          2. Patients diagnosed with degenerative arthritis&#xD;
&#xD;
          3. Patients with IKDC(Knee Documentation Committee subjective score) score of 60 or below&#xD;
&#xD;
          4. Patients with 100 mm VAS(Visual Analog Scale) score of 40 or above&#xD;
&#xD;
          5. With Grade 3 osteoarthritis as determined by the radiographic criteria of Kellgren and&#xD;
             Lawrence&#xD;
&#xD;
          6. With an International Cartilage Repair Society(ICRS) Grade III or IV cartilage damage&#xD;
             in the major lesions, as confirmed through an MRI scan&#xD;
&#xD;
          7. With a Body Mass Index(BMI) of higher than18.5 and lower than 30&#xD;
&#xD;
          8. Patients who satisfies the clinical/radiational criteria by the American College of&#xD;
             Rheumatology (ACR) guidelines, and applies to one of the following.&#xD;
&#xD;
               -  Older than 50&#xD;
&#xD;
               -  Morning stiffness for less than 30 minutes&#xD;
&#xD;
               -  Crepitus and Osteophytes&#xD;
&#xD;
          9. With major lesions concentrated in one section of the knee, and with the major lesions&#xD;
             considered the main cause of the clinical symptoms&#xD;
&#xD;
         10. With no alleviation of the symptoms even after at least three months of non-surgical&#xD;
             treatment&#xD;
&#xD;
         11. Healthy, with no major findings from the physical examination, hematology, serum&#xD;
             chemistry, and urine tests, and no significant medical history&#xD;
&#xD;
         12. Agreed to use an effective contraceptive method during the study period&#xD;
&#xD;
         13. Voluntarily agreed to participate in this study, and signed the informed consent form&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Showed clinically significant hematology, serum chemistry, and urine test results at&#xD;
             the screening visit&#xD;
&#xD;
          2. Regarding inclusion criteria 6. following patients should not be included&#xD;
&#xD;
               -  patients with a major lesion of ICRS grade 4 which is larger than 6cm2(for&#xD;
                  patient with ICRS grade 4)&#xD;
&#xD;
               -  patients with a major lesion of ICRS grade 3 which is larger than 6cm2(for&#xD;
                  patient without a ICRS grade 4),&#xD;
&#xD;
          3. Patient who had skin disease around target knee&#xD;
&#xD;
          4. patients who have a positive skin reaction to CS-10&#xD;
&#xD;
          5. Patients who had been administered with drugs such as oriental medicine, glucosamine&#xD;
             and chondroitin within 14 days of baseline visit&#xD;
&#xD;
          6. Patients taking steroidal anti-inflammatory medications within 14 days of baseline&#xD;
             visit&#xD;
&#xD;
          7. Patients with severe pain in other areas that could effect the diagnosis of the&#xD;
             symptoms of the&#xD;
&#xD;
          8. History of surgery like arthroendoscopy within the past 6 months on the target knee&#xD;
&#xD;
          9. Patients who had been administered with immunosuppressants, including antirheumatic&#xD;
             drugs (including methotrexate or antimetabolite), within the past 3 months&#xD;
&#xD;
         10. Patients who had been treated with physical therapy or herbal remedy (acupuncture,&#xD;
             heat etc.) within 2 weeks of baseline visit&#xD;
&#xD;
         11. History of injection within the past 3 months on the target knee&#xD;
&#xD;
         12. Pregnant or breastfeeding female&#xD;
&#xD;
         13. With another joint disease apart from degenerative arthritis (e.g., systemic rheumatic&#xD;
             inflammatory disease associated with the knee or chondrocalcinosis, hemachromatosis,&#xD;
             inflammatory arthritis, necrosis of the trochanter, Paget's disease adjacent to a&#xD;
             joint in the femur or tibia, ochronosis, hemophilic arthropathy, infectious arthritis,&#xD;
             Charcot's disease in the knee joint, villonodular synovitis, synovial chondromas)&#xD;
&#xD;
         14. With an infectious disease, including HIV or hepatitis&#xD;
&#xD;
         15. With any of the following clinically significant diseases:&#xD;
&#xD;
               -  heart disease (e.g., myocardial infarction, arrhythmia, other serious heart&#xD;
                  diseases, coronary artery bypass graft)&#xD;
&#xD;
               -  kidney disease (e.g., chronic renal failure, glomerulonephritis)&#xD;
&#xD;
               -  liver disease (e.g., liver cirrhosis, fatty liver, acute or chronic liver&#xD;
                  disease)&#xD;
&#xD;
               -  endocrine disease (e.g., hyperthyroidism, hypothyroidism, thyroiditis, diabetes&#xD;
                  insipidus, Cushing's disease)&#xD;
&#xD;
               -  insulin-dependent diabetes mellitus&#xD;
&#xD;
               -  medical history of past or current malignant tumor&#xD;
&#xD;
               -  In particular, the tumors that TissueGene-C may aggravate can be screened using&#xD;
                  the following tests:&#xD;
&#xD;
                    -  Leukemia (White Blood Cell level in the hematology)&#xD;
&#xD;
                    -  Osteochondroma, Chondromas, Chondroblastoma, Chondromyxoid fibroma,&#xD;
                       Chondrosarcoma (Alkaline phosphatase level in the hematology)&#xD;
&#xD;
         16. Participated in another clinical trial (using the investigational drug or a medical&#xD;
             device) within 30 days before enrollment in this study&#xD;
&#xD;
         17. Patients who administered the TissueGene-C from past clinical trial&#xD;
&#xD;
         18. Considered inappropriate by the investigator for participation in this study&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jin Gu Kim, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Inje University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Su Hee Kyung, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Kyungpook National University Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Chul Won Ha, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Samsung Medical Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Myung Chul Lee, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Seoul National University Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Yong In, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>The Catholic University of Korea Seoul ST. Mary's Hospita</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Seong Il Bin, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Asan Medical Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Seong Do Cho, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Ulsan University Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jae Doo Yoo, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Ewha Womans University Mokdong</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Myung Gu Kim, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Inha University Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Ju Hong Lee, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Chonbuk National University Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Ui Seong Choi, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Chungbuk National University Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Chung Hyeok Choi, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hanyang University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Chungbuk National University Hospital</name>
      <address>
        <city>Cheongju</city>
        <zip>361-711</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kyungpook National Univ. Hospital</name>
      <address>
        <city>Daegu</city>
        <zip>700-721</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Inha University Hospital</name>
      <address>
        <city>Incheon</city>
        <zip>400-711</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chonbuk National University Hospital</name>
      <address>
        <city>Jeonju</city>
        <zip>561-712</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Inje University Seoul Paik Hospital</name>
      <address>
        <city>Seoul</city>
        <zip>100-032</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Seoul National University Hospital</name>
      <address>
        <city>Seoul</city>
        <zip>110-744</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hanyang University Medical Center</name>
      <address>
        <city>Seoul</city>
        <zip>133-791</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Samsung Medical Center</name>
      <address>
        <city>Seoul</city>
        <zip>135-710</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Catholic University of Korea Seoul St. Mary's Hospital</name>
      <address>
        <city>Seoul</city>
        <zip>137-701</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ASAN Medical Center</name>
      <address>
        <city>Seoul</city>
        <zip>138-736</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ewha Womans University Mokdong Hospital</name>
      <address>
        <city>Seoul</city>
        <zip>158-710</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ulsan University Hospital</name>
      <address>
        <city>Ulsan</city>
        <zip>682-714</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>November 2017</verification_date>
  <study_first_submitted>February 17, 2014</study_first_submitted>
  <study_first_submitted_qc>February 24, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 26, 2014</study_first_posted>
  <last_update_submitted>November 14, 2017</last_update_submitted>
  <last_update_submitted_qc>November 14, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">November 17, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>chondrocyte cells, Osteoarthritis, gene therapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Arthritis</mesh_term>
    <mesh_term>Osteoarthritis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

